The emerging science of hot flash relief: Legitimizing the "obecalp" effect

Menopause

Volumn 12, Issue 1, 2005, Pages 4-7

  Reame, Nancy King ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESTROGEN; FLUOXETINE; GESTAGEN; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

BREAST CANCER; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG SAFETY; EDITORIAL; ESTROGEN THERAPY; FOOD AND DRUG ADMINISTRATION; HEALTH HAZARD; HORMONAL THERAPY; HOT FLUSH; HUMAN; INSOMNIA; MEDICAL PRACTICE; MENOPAUSE; META ANALYSIS; RISK ASSESSMENT; SIDE EFFECT;

AFFECT; CLINICAL TRIALS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; PLACEBO EFFECT; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS;

EID: 13444283601     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200512010-00003     Document Type: Editorial

References (32)

1. Kupperman HS, Wetchler BB, Blatt MHG: Contemporary therapy of the menopausal syndrome. JAMA 1959;171:1627-1637.
2. Sloan JA, Loprinzi CL, Novotny PJ, et al. Methodologie lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290.
3. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002;360(9348):1851-1861.
4. Stearns V, Hayes DF. Cooling off hot flashes. J Clin Oncol 2002:20:1436-1438.
5. Alder E. The Blatt-Kupperman menopausal index: a critique. Maturitas 1998;29:19-24.
6. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-813.
7. Santoro N, Clarkson TB, Freedman RR, Fugh-Berman A, Loprinzi CL, Reame NE. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11:11-33.
8. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990;592:52-86; discussion 123-133.
9. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29:319-336.
10. Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame N, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol 2000;152:463-473.
11. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol 2003;101:264-272.
12. Oldenhave A, Jaszmann LJ, Everaerd WT, Haspels AA. Hysterectomized women with ovarian conservation report more severe climacteric complaints than do normal climacteric women of similar age. Am J Obstet Gynecol 1993;168(3 Pt 1):765-771.
13. Hollander LE, Freeman EW, Sammel MD, Berlin JA, Grisso JA, Battistini M. Sleep quality, estradiol levels, and behavioral factors in late reproductive age women. Obstet Gynecol 2001;98:391-397.
14. Birge SJ. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia? J Am Geriatr Soc 1996;44:865-870.
15. Lee SJ, Kanis JA. An association between osteoporosis and premenstrual symptoms and postmenopausal symptoms. Bone Miner 1994;24:127-134.
16. Avis NE, Brambilla D, McKinlay SM, Vass K. A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study. Ann Epidemiol 1994;4:214-220.
17. Loprinzi CL, Barton DL, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet Oncol 2001;2:199-204.
18. Carpenter, JS, Andrykowski MA, Cordova M et al. Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management, and relation to quality of life. Cancer 1998;82:1682-1691.
19. MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2001;(1):CD002978. Accessed November 30, 2004.
20. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
21. Ettinger B, Grady D, Tosteson ANA, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-1232.
22. Loprinzi CL, Pisansky TM, Fonseca R, et al: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998;16:2377-2381.
23. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356(9247):2059-2063.
24. Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann Oncol 2000;11:17-22.
25. Loprinzi CL, Sloan JA, Perez EA. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-83.
26. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes. JAMA 2003;289:2827-2834.
27. ACOG Committee Report.Vasomotor Symptoms. Obstet Gynecol 2004;104(Suppl):106S-117S.
28. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, et al. Citalopram and fluoxetine in the treatment of menopausal symptoms: a prospective randomized 9-month placebo-controlled double-blind study. Menopause 2005;12:18-26.
29. Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Management 2001;22:979-989.
30. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-1602.
31. Carpenter JS, Monahan PO, Azzouz MS. Accuracy of subjective hot flash reports compared to continuous sternal skin conductance monitoring. NAMS 15th Annual Abstract Book. Pg 63, Oct 6-9, 2004.
32. Carpenter JS, Monahan PO, Azzouz MS. Is sternal skin conductance monitoring a valid measure of hot flash intensity and/or hot flash bother? NAMS 15th Annual Meeting, October 6-9, 2004. Oral presentation, page 63 [abstract book].